These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 39152679)

  • 1. Dose-dependent induction of CYP3A activity by St. John's wort alone and in combination with rifampin.
    Hohmann N; Friedrichs AS; Burhenne J; Blank A; Mikus G; Haefeli WE
    Clin Transl Sci; 2024 Aug; 17(8):e70007. PubMed ID: 39152679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity.
    Hafner V; Jäger M; Matthée AK; Ding R; Burhenne J; Haefeli WE; Mikus G
    Clin Pharmacol Ther; 2010 Feb; 87(2):191-6. PubMed ID: 19924124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of induction of CYP3A4 by St John's wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype.
    Markert C; Kastner IM; Hellwig R; Kalafut P; Schweizer Y; Hoffmann MM; Burhenne J; Weiss J; Mikus G; Haefeli WE
    Basic Clin Pharmacol Toxicol; 2015 May; 116(5):423-8. PubMed ID: 25286744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
    Wang Z; Gorski JC; Hamman MA; Huang SM; Lesko LJ; Hall SD
    Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose.
    Mueller SC; Majcher-Peszynska J; Uehleke B; Klammt S; Mundkowski RG; Miekisch W; Sievers H; Bauer S; Frank B; Kundt G; Drewelow B
    Eur J Clin Pharmacol; 2006 Jan; 62(1):29-36. PubMed ID: 16341856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers.
    Mueller SC; Majcher-Peszynska J; Mundkowski RG; Uehleke B; Klammt S; Sievers H; Lehnfeld R; Frank B; Thurow K; Kundt G; Drewelow B
    Eur J Clin Pharmacol; 2009 Jan; 65(1):81-7. PubMed ID: 18762932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The recovery time-course of CYP3A after induction by St John's wort administration.
    Imai H; Kotegawa T; Tsutsumi K; Morimoto T; Eshima N; Nakano S; Ohashi K
    Br J Clin Pharmacol; 2008 May; 65(5):701-7. PubMed ID: 18294328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity.
    Fuchs I; Hafner-Blumenstiel V; Markert C; Burhenne J; Weiss J; Haefeli WE; Mikus G
    Eur J Clin Pharmacol; 2013 Mar; 69(3):507-13. PubMed ID: 22968811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interaction between St John's wort and an oral contraceptive.
    Hall SD; Wang Z; Huang SM; Hamman MA; Vasavada N; Adigun AQ; Hilligoss JK; Miller M; Gorski JC
    Clin Pharmacol Ther; 2003 Dec; 74(6):525-35. PubMed ID: 14663455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues.
    Matheny CJ; Ali RY; Yang X; Pollack GM
    Drug Metab Dispos; 2004 Sep; 32(9):1008-14. PubMed ID: 15319343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.
    Dresser GK; Schwarz UI; Wilkinson GR; Kim RB
    Clin Pharmacol Ther; 2003 Jan; 73(1):41-50. PubMed ID: 12545142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John's wort.
    Gödtel-Armbrust U; Metzger A; Kroll U; Kelber O; Wojnowski L
    Naunyn Schmiedebergs Arch Pharmacol; 2007 Aug; 375(6):377-82. PubMed ID: 17593354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John's Wort.
    Adiwidjaja J; Boddy AV; McLachlan AJ
    Clin Pharmacokinet; 2019 Jul; 58(7):911-926. PubMed ID: 30675694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided.
    Huppertz A; Werntz L; Meid AD; Foerster KI; Burhenne J; Czock D; Mikus G; Haefeli WE
    Br J Clin Pharmacol; 2018 Dec; 84(12):2903-2913. PubMed ID: 30192025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guidance for Rifampin and Midazolam Dosing Protocols To Study Intestinal and Hepatic Cytochrome P450 (CYP) 3A4 Induction and De-induction.
    Kapetas AJ; Sorich MJ; Rodrigues AD; Rowland A
    AAPS J; 2019 Jun; 21(5):78. PubMed ID: 31218462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The time-dependent effects of St John's wort on cytochrome P450, uridine diphosphate-glucuronosyltransferase, glutathione S-transferase, and NAD(P)H-quinone oxidoreductase in mice.
    Yang JF; Liu YR; Huang CC; Ueng YF
    J Food Drug Anal; 2018 Jan; 26(1):422-431. PubMed ID: 29389584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug interaction between St John's wort and zolpidem in healthy subjects.
    Hojo Y; Echizenya M; Ohkubo T; Shimizu T
    J Clin Pharm Ther; 2011 Dec; 36(6):711-5. PubMed ID: 21058968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. St. John's Wort Formulations Induce Rat CYP3A23-3A1 Independent of Their Hyperforin Content.
    Schäfer AM; Rysz MA; Schädeli J; Hübscher M; Khosravi H; Fehr M; Seibert I; Potterat O; Smieško M; Meyer Zu Schwabedissen HE
    Mol Pharmacol; 2023 Dec; 105(1):14-22. PubMed ID: 37863663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. St. John's wort extract induces CYP3A and CYP2E1 in the Swiss Webster mouse.
    Bray BJ; Perry NB; Menkes DB; Rosengren RJ
    Toxicol Sci; 2002 Mar; 66(1):27-33. PubMed ID: 11861970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. St. John's wort extract with a high hyperforin content does not induce P-glycoprotein activity at the human blood-brain barrier.
    El Biali M; Wölfl-Duchek M; Jackwerth M; Mairinger S; Weber M; Bamminger K; Poschner S; Rausch I; Schindler N; Lozano IH; Jäger W; Nics L; Tournier N; Hacker M; Zeitlinger M; Bauer M; Langer O
    Clin Transl Sci; 2024 May; 17(5):e13804. PubMed ID: 38700454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.